From L-R: TriGemX Bio CFO Aninda Katragadda, CEO Jeff Goater and CMO Brett Lauring
October 19, 2026 07:00 AM EDT
TriGemX Bio is going public through SPAC to get its migraine prospect to market
The stock market will soon welcome another drug developer through a backdoor route that has been fallen out of favor now that traditional IPOs are …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
ENDPOINTS CAREERS